nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—CYP1A1—Riluzole—amyotrophic lateral sclerosis	0.517	0.691	CbGbCtD
Clenbuterol—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.231	0.309	CbGbCtD
Clenbuterol—NGF—sciatic nerve—amyotrophic lateral sclerosis	0.0507	0.494	CbGeAlD
Clenbuterol—NGF—peripheral nervous system—amyotrophic lateral sclerosis	0.0194	0.189	CbGeAlD
Clenbuterol—NGF—nerve—amyotrophic lateral sclerosis	0.0151	0.148	CbGeAlD
Clenbuterol—NGF—spinal cord—amyotrophic lateral sclerosis	0.00404	0.0394	CbGeAlD
Clenbuterol—NGF—nervous system—amyotrophic lateral sclerosis	0.00341	0.0332	CbGeAlD
Clenbuterol—NGF—central nervous system—amyotrophic lateral sclerosis	0.00328	0.032	CbGeAlD
Clenbuterol—NGF—brain—amyotrophic lateral sclerosis	0.0026	0.0254	CbGeAlD
Clenbuterol—ADRB1—nervous system—amyotrophic lateral sclerosis	0.000887	0.00865	CbGeAlD
Clenbuterol—ADRB1—central nervous system—amyotrophic lateral sclerosis	0.000854	0.00833	CbGeAlD
Clenbuterol—ADRB1—brain—amyotrophic lateral sclerosis	0.000678	0.00661	CbGeAlD
Clenbuterol—CYP1A1—nervous system—amyotrophic lateral sclerosis	0.000572	0.00558	CbGeAlD
Clenbuterol—CYP1A1—central nervous system—amyotrophic lateral sclerosis	0.000551	0.00537	CbGeAlD
Clenbuterol—TNF—Spinal Cord Injury—AQP4—amyotrophic lateral sclerosis	0.00047	0.00315	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—amyotrophic lateral sclerosis	0.000461	0.00309	CbGpPWpGaD
Clenbuterol—NGF—p75 NTR receptor-mediated signalling—CASP3—amyotrophic lateral sclerosis	0.000446	0.00299	CbGpPWpGaD
Clenbuterol—CYP1A1—brain—amyotrophic lateral sclerosis	0.000437	0.00426	CbGeAlD
Clenbuterol—NGF—Signaling by NGF—SQSTM1—amyotrophic lateral sclerosis	0.000437	0.00292	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—ERBB4—amyotrophic lateral sclerosis	0.000434	0.00291	CbGpPWpGaD
Clenbuterol—CYP1A1—Oxidative Stress—SOD1—amyotrophic lateral sclerosis	0.000425	0.00285	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—SOD1—amyotrophic lateral sclerosis	0.000412	0.00276	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—ATF1—amyotrophic lateral sclerosis	0.00041	0.00274	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000404	0.00271	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—CASP9—amyotrophic lateral sclerosis	0.000398	0.00266	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—CASP9—amyotrophic lateral sclerosis	0.000398	0.00266	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—CASP9—amyotrophic lateral sclerosis	0.00039	0.00261	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—CASP9—amyotrophic lateral sclerosis	0.000378	0.00254	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	0.000376	0.00252	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	0.000376	0.00252	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	0.000376	0.00252	CbGpPWpGaD
Clenbuterol—TNF—Vitamin B12 Metabolism—APOE—amyotrophic lateral sclerosis	0.000374	0.0025	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—APOE—amyotrophic lateral sclerosis	0.000362	0.00243	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—CASP9—amyotrophic lateral sclerosis	0.000352	0.00236	CbGpPWpGaD
Clenbuterol—TNF—Matrix Metalloproteinases—MMP9—amyotrophic lateral sclerosis	0.000343	0.0023	CbGpPWpGaD
Clenbuterol—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—CASP3—amyotrophic lateral sclerosis	0.000337	0.00225	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—ERBB4—amyotrophic lateral sclerosis	0.000334	0.00224	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—MAPT—amyotrophic lateral sclerosis	0.000329	0.0022	CbGpPWpGaD
Clenbuterol—NGF—p75(NTR)-mediated signaling—TP53—amyotrophic lateral sclerosis	0.000329	0.0022	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—SOD1—amyotrophic lateral sclerosis	0.000327	0.00219	CbGpPWpGaD
Clenbuterol—TNF—amb2 Integrin signaling—MMP9—amyotrophic lateral sclerosis	0.000326	0.00218	CbGpPWpGaD
Clenbuterol—TNF—Ceramide signaling pathway—IGF1—amyotrophic lateral sclerosis	0.000324	0.00217	CbGpPWpGaD
Clenbuterol—CYP1A1—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000322	0.00216	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—CD40LG—amyotrophic lateral sclerosis	0.00032	0.00214	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—MAPT—amyotrophic lateral sclerosis	0.000308	0.00206	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000306	0.00205	CbGpPWpGaD
Clenbuterol—TNF—Amyotrophic lateral sclerosis (ALS)—CASP3—amyotrophic lateral sclerosis	0.000301	0.00201	CbGpPWpGaD
Clenbuterol—TNF—Cardiac Hypertrophic Response—IGF1—amyotrophic lateral sclerosis	0.000291	0.00195	CbGpPWpGaD
Clenbuterol—NGF—BDNF signaling pathway—CASP3—amyotrophic lateral sclerosis	0.000284	0.00191	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—SQSTM1—amyotrophic lateral sclerosis	0.000283	0.0019	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—C3—amyotrophic lateral sclerosis	0.000283	0.00189	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000278	0.00186	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000278	0.00186	CbGpPWpGaD
Clenbuterol—TNF—TWEAK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000278	0.00186	CbGpPWpGaD
Clenbuterol—TNF—FAS pathway and Stress induction of HSP regulation—CASP3—amyotrophic lateral sclerosis	0.000278	0.00186	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.00027	0.00181	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	0.000267	0.00179	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—APOE—amyotrophic lateral sclerosis	0.000263	0.00176	CbGpPWpGaD
Clenbuterol—TNF—TWEAK Signaling Pathway—MMP9—amyotrophic lateral sclerosis	0.000262	0.00176	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—amyotrophic lateral sclerosis	0.00026	0.00174	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000254	0.0017	CbGpPWpGaD
Clenbuterol—CYP1A1—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000253	0.0017	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000251	0.00168	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—BDNF—amyotrophic lateral sclerosis	0.000243	0.00163	CbGpPWpGaD
Clenbuterol—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CASP3—amyotrophic lateral sclerosis	0.000241	0.00162	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000233	0.00156	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—CASP9—amyotrophic lateral sclerosis	0.000232	0.00155	CbGpPWpGaD
Clenbuterol—CYP1A1—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000229	0.00153	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	0.000226	0.00152	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.000219	0.00147	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—CASP9—amyotrophic lateral sclerosis	0.000217	0.00146	CbGpPWpGaD
Clenbuterol—TNF—Caspase Cascade in Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000217	0.00146	CbGpPWpGaD
Clenbuterol—TNF—MicroRNAs in cardiomyocyte hypertrophy—IGF1—amyotrophic lateral sclerosis	0.000207	0.00139	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—IGF1—amyotrophic lateral sclerosis	0.000207	0.00139	CbGpPWpGaD
Clenbuterol—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000205	0.00138	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000196	0.00131	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	0.000194	0.0013	CbGpPWpGaD
Clenbuterol—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—amyotrophic lateral sclerosis	0.000193	0.00129	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—BDNF—amyotrophic lateral sclerosis	0.000183	0.00123	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000182	0.00122	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.00018	0.00121	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000178	0.00119	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000176	0.00118	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.00017	0.00114	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000169	0.00113	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—CASP3—amyotrophic lateral sclerosis	0.000167	0.00112	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—CASP3—amyotrophic lateral sclerosis	0.000167	0.00112	CbGpPWpGaD
Clenbuterol—TNF—Selenium Micronutrient Network—PTGS2—amyotrophic lateral sclerosis	0.000165	0.00111	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000165	0.00111	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—CASP3—amyotrophic lateral sclerosis	0.000164	0.0011	CbGpPWpGaD
Clenbuterol—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000161	0.00108	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000161	0.00108	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	0.000161	0.00108	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000161	0.00108	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—CASP3—amyotrophic lateral sclerosis	0.000159	0.00107	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000158	0.00106	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000155	0.00104	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	0.000153	0.00102	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	0.00015	0.001	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—CASP3—amyotrophic lateral sclerosis	0.000148	0.000993	CbGpPWpGaD
Clenbuterol—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	0.000146	0.000979	CbGpPWpGaD
Clenbuterol—TNF—Adipogenesis—IGF1—amyotrophic lateral sclerosis	0.000146	0.000978	CbGpPWpGaD
Clenbuterol—CYP1A1—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	0.000143	0.000956	CbGpPWpGaD
Clenbuterol—TNF—Allograft Rejection—VEGFA—amyotrophic lateral sclerosis	0.000142	0.000952	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	0.000141	0.000945	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000138	0.000926	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000138	0.000925	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000137	0.000914	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000135	0.000906	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000134	0.000894	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000132	0.000882	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—PTGS2—amyotrophic lateral sclerosis	0.000131	0.000876	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—TP53—amyotrophic lateral sclerosis	0.000124	0.00083	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—CASP3—amyotrophic lateral sclerosis	0.000121	0.000813	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	0.00012	0.000805	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.00012	0.000801	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—MMP9—amyotrophic lateral sclerosis	0.000115	0.000769	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	0.000112	0.000754	CbGpPWpGaD
Clenbuterol—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	0.000112	0.000749	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—TP53—amyotrophic lateral sclerosis	0.000107	0.000719	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	0.000107	0.000719	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	0.000103	0.000689	CbGpPWpGaD
Clenbuterol—CYP1A1—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	0.000103	0.000687	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—TP53—amyotrophic lateral sclerosis	0.000102	0.000685	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000102	0.000681	CbGpPWpGaD
Clenbuterol—CYP1A1—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	0.000101	0.000677	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—CASP3—amyotrophic lateral sclerosis	9.76e-05	0.000654	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	9.73e-05	0.000652	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	9.71e-05	0.000651	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	9.67e-05	0.000648	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	9.57e-05	0.000641	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	9.38e-05	0.000628	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	9.32e-05	0.000624	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—CASP3—amyotrophic lateral sclerosis	9.15e-05	0.000613	CbGpPWpGaD
Clenbuterol—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	9.1e-05	0.00061	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	8.99e-05	0.000602	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	8.9e-05	0.000596	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	8.8e-05	0.000589	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	8.76e-05	0.000587	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	8.38e-05	0.000561	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—VCP—amyotrophic lateral sclerosis	8.31e-05	0.000556	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	8.26e-05	0.000553	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	8.24e-05	0.000552	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	8.04e-05	0.000539	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	7.93e-05	0.000531	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—TPK1—amyotrophic lateral sclerosis	7.86e-05	0.000526	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—VAPB—amyotrophic lateral sclerosis	7.86e-05	0.000526	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	7.81e-05	0.000523	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—TP53—amyotrophic lateral sclerosis	7.79e-05	0.000522	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	7.75e-05	0.000519	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	7.66e-05	0.000513	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	7.64e-05	0.000512	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	7.33e-05	0.000491	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—VAPA—amyotrophic lateral sclerosis	7.19e-05	0.000481	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	7.17e-05	0.00048	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	7.14e-05	0.000478	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	7.1e-05	0.000475	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	7.06e-05	0.000473	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	7.01e-05	0.00047	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	6.94e-05	0.000465	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	6.74e-05	0.000452	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.68e-05	0.000448	CbGpPWpGaD
Clenbuterol—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.54e-05	0.000438	CbGpPWpGaD
Clenbuterol—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	6.45e-05	0.000432	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—FIG4—amyotrophic lateral sclerosis	6.28e-05	0.000421	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—TP53—amyotrophic lateral sclerosis	6.26e-05	0.000419	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	6.16e-05	0.000413	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	6.04e-05	0.000404	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—C3—amyotrophic lateral sclerosis	5.96e-05	0.000399	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	5.9e-05	0.000395	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	5.9e-05	0.000395	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—TP53—amyotrophic lateral sclerosis	5.87e-05	0.000393	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	5.75e-05	0.000385	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—DAO—amyotrophic lateral sclerosis	5.68e-05	0.000381	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—APOE—amyotrophic lateral sclerosis	5.55e-05	0.000372	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.53e-05	0.00037	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	5.41e-05	0.000362	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	5.3e-05	0.000355	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—C3—amyotrophic lateral sclerosis	5.22e-05	0.00035	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.2e-05	0.000348	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	5.09e-05	0.000341	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	5.01e-05	0.000336	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	5.01e-05	0.000336	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.93e-05	0.00033	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	4.85e-05	0.000325	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	4.82e-05	0.000323	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.77e-05	0.00032	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	4.67e-05	0.000313	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	4.67e-05	0.000313	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	4.58e-05	0.000307	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	4.58e-05	0.000307	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	4.55e-05	0.000305	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	4.33e-05	0.00029	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—PLB1—amyotrophic lateral sclerosis	4.31e-05	0.000288	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.26e-05	0.000285	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.24e-05	0.000284	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.19e-05	0.000281	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	4.15e-05	0.000278	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	4.1e-05	0.000275	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	4.01e-05	0.000268	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—GSR—amyotrophic lateral sclerosis	3.97e-05	0.000266	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	3.71e-05	0.000248	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—MMP9—amyotrophic lateral sclerosis	3.65e-05	0.000245	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	3.62e-05	0.000243	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	3.62e-05	0.000242	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	3.53e-05	0.000236	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.5e-05	0.000235	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	3.49e-05	0.000234	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	3.43e-05	0.00023	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.41e-05	0.000228	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	3.34e-05	0.000223	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	3.33e-05	0.000223	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	3.28e-05	0.00022	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—CHAT—amyotrophic lateral sclerosis	3.26e-05	0.000219	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.1e-05	0.000207	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—C3—amyotrophic lateral sclerosis	3.08e-05	0.000206	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	3.03e-05	0.000203	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	2.99e-05	0.000201	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	2.98e-05	0.000199	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.88e-05	0.000193	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—APOE—amyotrophic lateral sclerosis	2.87e-05	0.000192	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	2.82e-05	0.000189	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	2.75e-05	0.000184	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.7e-05	0.000181	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	2.64e-05	0.000177	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.57e-05	0.000172	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	2.53e-05	0.00017	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	2.52e-05	0.000169	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	2.37e-05	0.000159	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	2.31e-05	0.000155	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—TP53—amyotrophic lateral sclerosis	2.26e-05	0.000152	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.2e-05	0.000147	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	2.15e-05	0.000144	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	2.08e-05	0.000139	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.07e-05	0.000139	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	2.04e-05	0.000137	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	2.03e-05	0.000136	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	1.9e-05	0.000127	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.83e-05	0.000123	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.83e-05	0.000122	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—C3—amyotrophic lateral sclerosis	1.79e-05	0.00012	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.75e-05	0.000117	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.72e-05	0.000116	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.7e-05	0.000114	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	1.67e-05	0.000112	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.61e-05	0.000108	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	1.55e-05	0.000104	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.41e-05	9.43e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	1.38e-05	9.22e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—APOE—amyotrophic lateral sclerosis	1.33e-05	8.88e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	1.3e-05	8.71e-05	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TP53—amyotrophic lateral sclerosis	1.17e-05	7.84e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.12e-05	7.49e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.08e-05	7.26e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	1.06e-05	7.1e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.03e-05	6.88e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1.02e-05	6.86e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	1e-05	6.71e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	9.19e-06	6.16e-05	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.08e-06	6.09e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	8.99e-06	6.02e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	8.45e-06	5.66e-05	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.95e-06	4.65e-05	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	6.8e-06	4.55e-05	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.79e-06	3.88e-05	CbGpPWpGaD
